• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Final Participating Company Line-Up Announced for the Virtual Investor Pitch Conference Hosted by JTC Team Being Held June 17 - 18, 2024

    6/17/24 8:00:00 AM ET
    $AIM
    $ANVS
    $AREC
    $GRI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AIM alert in real time by email

    - Two-day conference with live video webcast presentations and Q&A beginning today, June 17th at 9:00 AM ET

    - Full schedule of participating companies now available at www.virtualinvestorco.com

    FRENCHTOWN, NJ / ACCESSWIRE / June 17, 2024 / JTC Team ("JTC"), a fully integrated corporate communications and investor relations firm, today announced the final participating company line-up for the two-day Virtual Investor Pitch Conference beginning today, Monday, June 17, 2024.

    For the event, participating companies will provide their "elevator pitch" and outline upcoming milestones. Additionally, investors and interested parties will have the opportunity to submit questions live during the event. Participating companies will answer as many questions as possible in the time allowed.

    The final schedule of participating companies is as follows:

    Monday, June 17

    • 9:00 AM ET: Kaida BioPharma, Inc. (Private) - Webcast
    • 10:00 AM ET: Adolore BioTherapeutics, Inc. (Private) - Webcast
    • 12:00 PM ET: Palisade Bio, Inc. (NASDAQ:PALI) - Webcast
    • 1:00 PM ET: AIM ImmunoTech Inc. (NYSE:AIM) - Webcast
    • 4:00 PM ET: enVVeno Medical Corporation (NASDAQ:NVNO) - Webcast

    Tuesday, June 18

    • 10:00 AM ET: Royalty Management Holding Corporation (NASDAQ:RMCO) - Webcast
    • 11:00 AM ET: GRI Bio, Inc. (NASDAQ:GRI) - Webcast
    • 12:00 PM ET: Outlook Therapeutics, Inc. (NASDAQ:OTLK) - Webcast
    • 1:00 PM ET: American Resources Corporation (NASDAQ:AREC) - Webcast
    • 2:00 PM ET: Annovis Bio Inc. (NYSE:ANVS) - Webcast
    • 3:00 PM ET: Moleculin Biotech, Inc. (NASDAQ:MBRX) - Webcast

    All investors and interested parties can access the event schedule and individual company webcast details at www.virtualinvestorco.com. Webcast replays will be made available shortly after the conclusion of the live event and will be accessible for 90 days.

    To access all Virtual Investor events, visit www.virtualinvestorco.com.

    About JTC Team

    JTC is a fully integrated investor relations firm that is dedicated to helping you tell your story to the right audiences in order to build awareness. JTC has developed a reputation of excellence for executing on robust communication strategies that deliver results. The Company partners with both public and private companies across the Life Sciences and Technology industries to help raise awareness and build stakeholder value. For more information, please visit www.jtcir.com or connect with the company on X and LinkedIn.

    Contact:

    Jenene Thomas
    JTC Team, LLC
    T: +1 (833) 475-8247
    [email protected]

    SOURCE: JTC Team, LLC



    View the original press release on accesswire.com

    Get the next $AIM alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AIM
    $ANVS
    $AREC
    $GRI

    CompanyDatePrice TargetRatingAnalyst
    Moleculin Biotech Inc.
    $MBRX
    2/12/2025Buy → Hold
    Maxim Group
    Annovis Bio Inc.
    $ANVS
    2/10/2025Buy → Hold
    D. Boral Capital
    GRI Bio Inc.
    $GRI
    12/9/2024$10.00Buy
    H.C. Wainwright
    Outlook Therapeutics Inc.
    $OTLK
    12/2/2024Buy → Neutral
    Chardan Capital Markets
    Annovis Bio Inc.
    $ANVS
    10/25/2024$25.00Hold → Buy
    Maxim Group
    Outlook Therapeutics Inc.
    $OTLK
    3/27/2024$50.00Neutral → Buy
    BTIG Research
    Outlook Therapeutics Inc.
    $OTLK
    2/15/2024$3.00Neutral → Buy
    Chardan Capital Markets
    Outlook Therapeutics Inc.
    $OTLK
    1/25/2024Neutral → Buy
    Guggenheim
    More analyst ratings

    $AIM
    $ANVS
    $AREC
    $GRI
    Leadership Updates

    Live Leadership Updates

    See more
    • Annovis Bio Appoints Hui Liu as Director of Biostatistics

      MALVERN, Pa., April 29, 2025 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company developing transformative therapies for neurodegenerative disorders such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced the appointment Hui Liu as Director of Biostatistics. "Bringing Ms. Liu on board at this critical stage, as our pivotal Phase 3 AD trial advances, reinforces our commitment to scientific excellence," said Cheng Fang, Ph.D., Senior Vice President, Research and Development. "Her statistical expertise will help ensure the integrity of our data and support robust regulatory submissions as we move to

      4/29/25 8:00:00 AM ET
      $ANVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • AIM ImmunoTech Appoints David Chemerow to Board of Directors as an Independent Director

      OCALA, Fla., Feb. 26, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today announced that the Company's Board of Directors (the "Board") has, by unanimous vote, appointed David Chemerow as an Independent Director to the Board, effective immediately. Mr. Chemerow brings more than 40 years of finance, accounting and operations leadership experience across multiple industries. He previously served as the Chief Financial Officer and Treasurer, and prior to that as Chief Revenue Officer, of Comscore, Inc., an American-based global media measurement and analytics company. Prior to his tenure at Comscore, Mr. Chemerow served as the Chief Operating Officer an

      2/26/25 8:30:00 AM ET
      $AIM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Outlook Therapeutics® Appoints Faisal G. Sukhtian as Chairman of the Board of Directors

      ISELIN, N.J., Jan. 31, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union (EU) and the United Kingdom (UK) for the first authorized use of an ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD), today announced Faisal G. Sukhtian has been appointed as Chairman of the Board of Directors, effective immediately. Mr. Sukhtian will assume the role from Randy Thurman, who will remain on the Board as Lead Independent Director. "On behalf of the Board of Directors, management, and employees of Outlook Therapeutics, I want to extend my deepest

      1/31/25 8:05:00 AM ET
      $OTLK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AIM
    $ANVS
    $AREC
    $GRI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by AIM ImmunoTech Inc.

      SC 13D/A - AIM ImmunoTech Inc. (0000946644) (Subject)

      12/17/24 4:11:23 PM ET
      $AIM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Moleculin Biotech Inc.

      SC 13G/A - Moleculin Biotech, Inc. (0001659617) (Subject)

      11/14/24 5:12:06 PM ET
      $MBRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Outlook Therapeutics Inc.

      SC 13G/A - Outlook Therapeutics, Inc. (0001649989) (Subject)

      11/14/24 4:55:26 PM ET
      $OTLK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AIM
    $ANVS
    $AREC
    $GRI
    Financials

    Live finance-specific insights

    See more
    • Outlook Therapeutics Reports Financial Results for Second Quarter Fiscal Year 2025 and Provides Corporate Update

      LYTENAVA™ (bevacizumab gamma) on track for planned first commercial launches in Germany and the United Kingdom (UK) in Q2 CY2025Prescription Drug User Fee Act (PDUFA) goal date of August 27, 2025 in the United States ISELIN, N.J., May 15, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today reported financial results for the second quarter of fiscal year 2025 and provided a corporate update. "Outlook Therapeutics remains on track in 2025 to transform into a commercial-stage company with the planned upcoming commercial launch of LYTENAVA™ (bevaciz

      5/15/25 4:01:00 PM ET
      $OTLK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Moleculin Reports First Quarter 2025 Financial Results and Provides Corporate Update

      Enrollment and dosing underway in Phase 3 clinical trial (the "MIRACLE" trial) evaluating Annamycin (naxtarubicin) for the treatment of R/R AML  Regulatory and site selection progress to date supports interim data readout expected in the second half of 2025 Recently received European Medicines Agency (EMA) approval adds nine additional countries to the Company's ongoing MIRACLE trial; Authorization granted in all EU countries requested Company to host conference call and webcast today, May 14th at 8:30 AM ET HOUSTON, May 14, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), a late-stage pharmaceutical company with a broad portfolio of drug

      5/14/25 7:30:00 AM ET
      $MBRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Moleculin to Report First Quarter 2025 Financial Results on May 13, 2025 and Host Conference Call and Webcast

      HOUSTON, May 07, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat cancers and viruses, today announced that it will report its financial results for the first quarter ended March 31, 2025 on Tuesday afternoon, May 13, 2025. Moleculin management will host a conference call and live audio webcast to discuss the operational and financial results on Wednesday morning, May 14, 2025 at 8:30 AM ET. Interested participants and investors may access the conference call by dialing (877) 407-0832 (domestic) or (201) 689-8433 (international) and referenci

      5/7/25 9:00:00 AM ET
      $MBRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AIM
    $ANVS
    $AREC
    $GRI
    SEC Filings

    See more
    • Amendment: SEC Form S-1/A filed by Moleculin Biotech Inc.

      S-1/A - Moleculin Biotech, Inc. (0001659617) (Filer)

      6/6/25 9:20:54 AM ET
      $MBRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by Royalty Management Holding Corporation

      DEF 14A - Royalty Management Holding Corp (0001843656) (Filer)

      6/6/25 8:00:38 AM ET
      $RMCO
      Multi-Sector Companies
      Miscellaneous
    • Moleculin Biotech Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Moleculin Biotech, Inc. (0001659617) (Filer)

      6/5/25 11:01:58 AM ET
      $MBRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AIM
    $ANVS
    $AREC
    $GRI
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $AIM
    $ANVS
    $AREC
    $GRI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Annovis to Host Webinar and Live Q&A on June 24, 2025

      MALVERN, Pa., June 05, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced it will host a live webcast where Maria Maccecchini, Ph.D., President and CEO, will provide updates and answer questions from the audience. Webcast Details Date: June 24, 2025Time: 4:30 PM EDTRegistration: Click here to register During the webcast, Dr. Maccecchini will share progress on the ongoing pivotal Phase 3 trial in early AD, the FDA's feedback on the continued development of the PD program, and other

      6/5/25 8:00:00 AM ET
      $ANVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Moleculin Releases On-Demand KOL Webcast to Discuss Data from its Phase 1B/2 Study of Annamycin for the Treatment of Soft Tissue Sarcoma (STS) Lung Metastases (MB-107)

      Access the on-demand webcast here HOUSTON, June 05, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat cancers and viruses, today announced the release of its Soft Tissue Sarcoma (STS) Lung Mets KOL Webcast discussing the final data from its U.S. Phase 1B/2 clinical trial evaluating Annamycin as monotherapy for the treatment of soft tissue sarcoma lung metastases (MB-107). For the event, Walter Klemp, Chairman and Chief Executive Officer, and Dr. Paul Waymack, Senior Chief Medical Officer of Moleculin are joined by Key Opinion Leaders: Mohamad

      6/5/25 8:00:00 AM ET
      $MBRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Outlook Therapeutics® Announces Commercial Launch of LYTENAVA™ (bevacizumab gamma) in Germany and the UK for the Treatment of Wet AMD

      LYTENAVA™ is the first and only approved ophthalmic formulation of bevacizumab for the treatment of wet AMD in the European Union (EU) and United Kingdom (UK)2.8 million injections of repackaged off-label bevacizumab in Europe each year1 ISELIN, N.J., June 02, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that LYTENAVA™ (bevacizumab gamma) is now commercially available in Germany and the UK for the treatment of wet age-related macular degeneration (wet AMD). LYTENAVA™ (bevacizumab gamma) is the first and only authorized ophthalmic

      6/2/25 7:00:00 AM ET
      $OTLK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Kellner Ted D bought $50,000 worth of shares (1,968,504 units at $0.03), increasing direct ownership by 196,850% to 1,969,504 units (SEC Form 4)

      4 - AIM ImmunoTech Inc. (0000946644) (Issuer)

      4/23/25 4:35:16 PM ET
      $AIM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Mitchell William M bought $5,000 worth of shares (196,851 units at $0.03), increasing direct ownership by 61% to 521,723 units (SEC Form 4)

      4 - AIM ImmunoTech Inc. (0000946644) (Issuer)

      4/23/25 4:35:19 PM ET
      $AIM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • CEO & President Equels Thomas K bought $50,000 worth of shares (1,968,504 units at $0.03), increasing direct ownership by 104% to 3,867,533 units (SEC Form 4)

      4 - AIM ImmunoTech Inc. (0000946644) (Issuer)

      4/23/25 4:35:17 PM ET
      $AIM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AIM
    $ANVS
    $AREC
    $GRI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Moleculin Biotech downgraded by Maxim Group

      Maxim Group downgraded Moleculin Biotech from Buy to Hold

      2/12/25 8:44:00 AM ET
      $MBRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Annovis Bio downgraded by D. Boral Capital

      D. Boral Capital downgraded Annovis Bio from Buy to Hold

      2/10/25 8:18:59 AM ET
      $ANVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • H.C. Wainwright initiated coverage on GRI Bio with a new price target

      H.C. Wainwright initiated coverage of GRI Bio with a rating of Buy and set a new price target of $10.00

      12/9/24 7:50:37 AM ET
      $GRI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AIM
    $ANVS
    $AREC
    $GRI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President & CEO Maccecchini Maria-Luisa was granted 46,000 shares, increasing direct ownership by 4% to 1,114,459 units (SEC Form 4)

      4 - Annovis Bio, Inc. (0001477845) (Issuer)

      6/5/25 6:00:15 AM ET
      $ANVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Hoffman Michael B was granted 5,000 shares, increasing direct ownership by 0.35% to 1,421,283 units (SEC Form 4)

      4 - Annovis Bio, Inc. (0001477845) (Issuer)

      6/2/25 4:35:53 PM ET
      $ANVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Sukhtian Ghiath M. was granted 4,285,714 shares (SEC Form 4)

      4 - Outlook Therapeutics, Inc. (0001649989) (Issuer)

      5/28/25 5:20:21 PM ET
      $OTLK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care